Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expands Aethlon Hemopurifier IDE To Address Ebola

This article was originally published in The Gray Sheet

Executive Summary

The agency approved an expanded clinical trial allowing Aethlon to test an Ebola treatment protocol at 10 U.S. sites; requires the company to gain institutional review board approval from each institution and the trials can only enroll up to 20 patients.

You may also be interested in...



FDA Emergency Authorizes Roche Ebola Assay

FDA grants its seventh Ebola diagnostic EUA, this time to Roche, as global health officials continue efforts to try to contain the outbreak of the deadly disease in West Africa.

WHO Launches Initiatives For Ebola POC Tests

The World Health Organization has initiated a rapid review process and is providing early test validation materials to encourage more manufacturers to quickly develop rapid, point-of-care Ebola tests. Meanwhile, Aethlon Medical is providing its bio-filtration device to treat blood of Ebola patients.

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.

 

Topics

UsernamePublicRestriction

Register

MT033683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel